Cargando…

Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study

BACKGROUND: The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Coloretti, Irene, Busani, Stefano, Biagioni, Emanuela, Venturelli, Sophie, Munari, Elena, Sita, Marco, DallAra, Lorenzo, Tosi, Martina, Clini, Enrico, Tonelli, Roberto, Fantini, Riccardo, Mussini, Cristina, Meschiari, Marianna, Guaraldi, Giovanni, Cossarizza, Andrea, Alfano, Gaetano, Girardis, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139121/
https://www.ncbi.nlm.nih.gov/pubmed/34040779
http://dx.doi.org/10.4081/mrm.2021.737
_version_ 1783695941980651520
author Coloretti, Irene
Busani, Stefano
Biagioni, Emanuela
Venturelli, Sophie
Munari, Elena
Sita, Marco
DallAra, Lorenzo
Tosi, Martina
Clini, Enrico
Tonelli, Roberto
Fantini, Riccardo
Mussini, Cristina
Meschiari, Marianna
Guaraldi, Giovanni
Cossarizza, Andrea
Alfano, Gaetano
Girardis, Massimo
author_facet Coloretti, Irene
Busani, Stefano
Biagioni, Emanuela
Venturelli, Sophie
Munari, Elena
Sita, Marco
DallAra, Lorenzo
Tosi, Martina
Clini, Enrico
Tonelli, Roberto
Fantini, Riccardo
Mussini, Cristina
Meschiari, Marianna
Guaraldi, Giovanni
Cossarizza, Andrea
Alfano, Gaetano
Girardis, Massimo
author_sort Coloretti, Irene
collection PubMed
description BACKGROUND: The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit. METHODS: The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching. RESULTS: Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission. CONCLUSIONS: Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation.
format Online
Article
Text
id pubmed-8139121
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-81391212021-05-25 Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study Coloretti, Irene Busani, Stefano Biagioni, Emanuela Venturelli, Sophie Munari, Elena Sita, Marco DallAra, Lorenzo Tosi, Martina Clini, Enrico Tonelli, Roberto Fantini, Riccardo Mussini, Cristina Meschiari, Marianna Guaraldi, Giovanni Cossarizza, Andrea Alfano, Gaetano Girardis, Massimo Multidiscip Respir Med Original Research Article BACKGROUND: The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit. METHODS: The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching. RESULTS: Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission. CONCLUSIONS: Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation. PAGEPress Publications, Pavia, Italy 2021-05-17 /pmc/articles/PMC8139121/ /pubmed/34040779 http://dx.doi.org/10.4081/mrm.2021.737 Text en Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).
spellingShingle Original Research Article
Coloretti, Irene
Busani, Stefano
Biagioni, Emanuela
Venturelli, Sophie
Munari, Elena
Sita, Marco
DallAra, Lorenzo
Tosi, Martina
Clini, Enrico
Tonelli, Roberto
Fantini, Riccardo
Mussini, Cristina
Meschiari, Marianna
Guaraldi, Giovanni
Cossarizza, Andrea
Alfano, Gaetano
Girardis, Massimo
Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study
title Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study
title_full Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study
title_fullStr Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study
title_full_unstemmed Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study
title_short Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study
title_sort effects of cytokine blocking agents on hospital mortality in patients admitted to icu with acute respiratory distress syndrome by sars-cov-2 infection: retrospective cohort study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139121/
https://www.ncbi.nlm.nih.gov/pubmed/34040779
http://dx.doi.org/10.4081/mrm.2021.737
work_keys_str_mv AT colorettiirene effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT busanistefano effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT biagioniemanuela effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT venturellisophie effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT munarielena effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT sitamarco effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT dallaralorenzo effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT tosimartina effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT clinienrico effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT tonelliroberto effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT fantiniriccardo effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT mussinicristina effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT meschiarimarianna effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT guaraldigiovanni effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT cossarizzaandrea effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT alfanogaetano effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy
AT girardismassimo effectsofcytokineblockingagentsonhospitalmortalityinpatientsadmittedtoicuwithacuterespiratorydistresssyndromebysarscov2infectionretrospectivecohortstudy